ProCE Banner Activity

HERTHENA-Lung01: Phase II Trial of Patritumab Deruxtecan in Previously Treated EGFR-Mutated Advanced NSCLC

Conference Coverage

Fixed-dose HER3-DXd at 5.6 mg/kg every 3 weeks demonstrated a confirmed ORR of 30% and a median duration of response lasting more than 6 months in patients with EGFR-mutated advanced NSCLC after failure of EGFR TKI therapy and platinum-based chemotherapy.

Released: September 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc